A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

Study Summary

This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.

Interventions

Study Locations

Facility	City	State	Country
City of Hope National Medical Center	Duarte	California	United States
University of California San Diego (UCSD)	La Jolla	California	United States
Winship Cancer Institute at Emory University	Atlanta	Georgia	United States
University of Chicago	Chicago	Illinois	United States
John Theurer Cancer Center, Hackensack University Medical Center	Hackensack	New Jersey	United States
Roswell Park Cancer Institute	Buffalo	New York	United States
The University of Texas MD Anderson Cancer Center	Houston	Texas	United States

Official Trial Information

View on ClinicalTrials.gov